Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has issued an announcement.
Shanghai Henlius Biotech, Inc. has announced the dosing of the first patient in Japan for its international multi-center phase 3 clinical study of HLX22, a recombinant humanized anti-HER2 monoclonal antibody injection, in combination with Trastuzumab and chemotherapy for treating HER2-positive, locally advanced or metastatic gastroesophageal junction and gastric cancer. This development marks a significant step in the company’s research efforts, potentially enhancing its position in the oncology market and offering new treatment options for patients with these aggressive cancers.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. operates in the biotechnology industry, focusing on the development of innovative biologic medicines. The company specializes in monoclonal antibodies and biosimilars, with a market focus on cancer treatment and other serious diseases.
YTD Price Performance: 21.94%
Average Trading Volume: 1,436,891
Technical Sentiment Signal: Sell
Current Market Cap: HK$15.71B
For detailed information about 2696 stock, go to TipRanks’ Stock Analysis page.